Article
Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.
Journal of medical genetics - 21 Mar 2024
Woodward Emma R, Lalloo Fiona, Forde Claire, Pugh Sarah, Burghel George J, Schlecht Helene, Harkness Elaine F, Howell Anthony, Howell Sacha J, Gandhi Ashu, Evans D Gareth
Abstract excerpt
BACKGROUND: The identification of germline pathogenic gene variants (PGVs) in triple negative breast cancer (TNBC) is important to inform further primary cancer risk reduction and TNBC treatment strategies. We therefore investigated the contribution of breast cancer associated PGVs to familial and isolated invasive TNBC. METHODS: Outcomes of germline BRCA1, BRCA2 and CHEK2_c.1100delC testing were recorded in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
